A Phase 3 interventional study of Lisdexamfetamine dimesylate (LDX) and Placebo in ADHD, sponsored by Shire. Completed at 51 sites in 9 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 10th largest by enrollment, is one of 6 that started in 2009, is one of 15 in phase 3, and was the 17th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 6 started in 2009.
This study's enrollment of 276 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one is the 21st largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2009, is one of 32 in phase 3, and was the 27th registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to evaluate the long-term maintenance of efficacy of LDX after administered to children and adolescents aged 6-17 with ADHD for at least 6 months
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label 30, 50, or 70mg
Drug: Lisdexamfetamine dimesylate (LDX)
Drug: Placebo
LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
Also known as: Vyvanse, SPD489
Placebo capsule once per day (double-blind period)
Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period
Treatment failure defined as 50% increase (worsening) in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) total score and \>= 2 point increase (worsening) in the Clinical Global Impression-Severity of Illness (CGI-S) score observed at any visit during the randomized withdrawal period compared to the respective scores at baseline of randomized withdrawal period. Subjects without an endpoint value were classed as treatment failures.
Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Change From Open-Label Baseline in The Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at Endpoint (Week-26) of The Open-label Period
ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.
Time frame: Open-label baseline and Endpoint (Week-26)
Change From Randomized Withdrawal Baseline in The ADHD-RS-IV Total Score at Endpoint of The Randomized Withdrawal Period
ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.
Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Endpoint (Week-26) of The Open-label Period
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: At Week 26
Percent of Participants With CGI-S at Endpoint of The Randomized Withdrawal Period, Last Observation Carried Forward (LOCF)
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: At endpoint of the randomized withdrawal period (Up to 6 weeks)
Percent of Participants With Improvement on Clinical Global Impression - Improvement (CGI-I) at Endpoint (Week-26) of The Open-label Period
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Improvement includes CGI-I categories of very much improved and much improved. No improvement includes all other assessed categories.
Time frame: At Week 26
Change From Open-label Baseline in The Health Utilities Index-2 (HUI-2) Scores at Endpoint (Week-26) of The Open-label Period, LOCF
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
Time frame: At open-label baseline and endpoint (Week-26) of the open-label period
Change From Randomized Withdrawal Baseline in The HUI-2 Scores at Endpoint of The Randomized Withdrawal Period
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Change From Open-label Baseline in The Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at Endpoint (Week-26) of The Open-label Period
The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.
Time frame: At open-label baseline and endpoint (Week-26) of the open-label period
Change From Randomized Withdrawal Baseline in The CHIP-CE:PRF Global T-score at Endpoint of The Randomized Withdrawal Period
The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.
Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Change From Open-Label Baseline in The Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Endpoint (Week-26) of The Open-label Period
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
Time frame: At open-label baseline and endpoint (Week-26) of the open-label period
Change From Randomized Withdrawal Baseline in The WFIRS-P Global Score at Endpoint of The Randomized Withdrawal Period
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Change From Open-Label Baseline in The Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Endpoint (Week-26) of The Open-label Period
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.
Time frame: At open-label baseline and endpoint (Week-26) of the open-label period
Change From Randomized Withdrawal Baseline in BPRS-C Total Score at Endpoint of The Randomized Withdrawal Period
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.
Time frame: Baseline of the randomized withdrawal period and its relevant endpoint (Up to 6 weeks)
Percent of Participants With CGI-S at Open-label Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).
Time frame: Open-label baseline
Percent of Participants With CGI-S at Randomized Withdrawal Baseline
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
Time frame: Randomized withdrawal baseline
Columbia-Suicide Severity Rating Scale (C-SSRS) During The Open-label Period
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: From open-label baseline to Week-26
C-SSRS During the Randomized Withdrawal Period
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: Baseline of the randomized withdrawal period to end of the study (Up to 6 weeks)
| Milestone | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|---|
| Started | 276 | 0 | 0 |
| Completed | 165 | 0 | 0 |
| Not completed | 111 | 0 | 0 |
| Withdrew: Adverse event | 44 | 0 | 0 |
| Withdrew: Withdrawal by subject | 22 | 0 | 0 |
| Withdrew: Lack of efficacy | 21 | 0 | 0 |
| Withdrew: Lost to follow-up | 11 | 0 | 0 |
| Withdrew: Protocol violation | 7 | 0 | 0 |
| Withdrew: Mother is a drug addict | 1 | 0 | 0 |
| Withdrew: Decision of medical monitor | 1 | 0 | 0 |
| Withdrew: Home situation intolerable | 1 | 0 | 0 |
| Withdrew: Adhd-rs score too high for random phase | 1 | 0 | 0 |
| Withdrew: Met stopping criteria for cgi-s score | 1 | 0 | 0 |
| Withdrew: Did not provide end of study page | 1 | 0 | 0 |
| Milestone | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|---|
| Started | 0 | 78 | 79 |
| Completed | 0 | 60 | 16 |
| Not completed | 0 | 18 | 63 |
| Withdrew: Met relapse criteria per investigator | 0 | 8 | 35 |
| Withdrew: Lack of efficacy | 0 | 5 | 18 |
| Withdrew: Withdrawal by subject | 0 | 1 | 7 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Did not complete a visit | 0 | 1 | 0 |
| Withdrew: Family reasons | 0 | 0 | 1 |
Treatment failure defined as 50% increase (worsening) in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) total score and \>= 2 point increase (worsening) in the Clinical Global Impression-Severity of Illness (CGI-S) score observed at any visit during the randomized withdrawal period compared to the respective scores at baseline of randomized withdrawal period. Subjects without an endpoint value were classed as treatment failures.
| percentage of participants | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Percent of Participants With Treatment Failures at End of The Randomized Withdrawal Period | 15.8 | 67.5 |
ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Change From Open-Label Baseline in The Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at Endpoint (Week-26) of The Open-label Period | -26.6 ± 11.39 |
ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Change From Randomized Withdrawal Baseline in The ADHD-RS-IV Total Score at Endpoint of The Randomized Withdrawal Period | 1.2 ± 1.09 | 13.8 ± 1.06 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| percentage of participants | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Normal, not at all ill | 39.9 |
| Borderline mentally ill | 46.5 |
| Mildly ill | 1.5 |
| Moderately ill | 6.6 |
| Markedly ill | 4.5 |
| Severely ill | 0.5 |
| Among the most extremely ill | 0.5 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).
| percentage of participants | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Normal, not at all ill | 0 |
| Borderline mentally ill | 0 |
| Mildly ill | 1.5 |
| Moderately ill | 27.2 |
| Markedly ill | 50.2 |
| Severely ill | 17.6 |
| Among the most extremely ill | 3.4 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| percentage of participants | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Normal, not at all ill | 40.0 | 8.2 |
| Borderline mentally ill | 41.3 | 19.2 |
| Mildly ill | 8.0 | 11.0 |
| Moderately ill | 10.7 | 39.7 |
| Markedly ill | 0 | 15.1 |
| Severely ill | 0 | 6.8 |
| Among the most extremely ill | 0 | 0 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Improvement includes CGI-I categories of very much improved and much improved. No improvement includes all other assessed categories.
| percentage of improved participants | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Percent of Participants With Improvement on Clinical Global Impression - Improvement (CGI-I) at Endpoint (Week-26) of The Open-label Period | 79.8 |
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
| scores on a scale | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Change From Open-label Baseline in The Health Utilities Index-2 (HUI-2) Scores at Endpoint (Week-26) of The Open-label Period, LOCF | 0.087 ± 0.1307 |
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Change From Randomized Withdrawal Baseline in The HUI-2 Scores at Endpoint of The Randomized Withdrawal Period | -0.005 ± 0.0772 | -0.046 ± 0.1098 |
The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.
| T-scores | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Change From Open-label Baseline in The Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at Endpoint (Week-26) of The Open-label Period | 10.2 ± 10.71 |
The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.
| T-scores | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Change From Randomized Withdrawal Baseline in The CHIP-CE:PRF Global T-score at Endpoint of The Randomized Withdrawal Period | 1.1 ± 1.17 | -5.4 ± 1.10 |
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
| scores on a scale | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Change From Open-Label Baseline in The Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Endpoint (Week-26) of The Open-label Period | -0.43 ± 0.42 |
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Change From Randomized Withdrawal Baseline in The WFIRS-P Global Score at Endpoint of The Randomized Withdrawal Period | 0.01 ± 0.03 | 0.20 ± 0.03 |
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Change From Open-Label Baseline in The Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Endpoint (Week-26) of The Open-label Period | -13.9 ± 12.58 |
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.
| Scores on a scale | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Change From Randomized Withdrawal Baseline in BPRS-C Total Score at Endpoint of The Randomized Withdrawal Period | -17.1 ± 11.17 | -9.1 ± 11.26 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)
| percentage of participants | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Normal, not at all ill | 50.0 | 46.8 |
| Borderline mentally ill | 50.0 | 53.2 |
| Mildly ill | 0 | 0 |
| Moderately ill | 0 | 0 |
| Markedly ill | 0 | 0 |
| Severely ill | 0 | 0 |
| Among the most extremely ill | 0 | 0 |
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
| participants | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) |
|---|---|
| Suicidal ideation | 1 |
| Suicidal behavior | 0 |
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
| participants | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|
| Suicidal ideation | 0 | 0 |
| Suicidal behavior | 0 | 0 |
Collected over 33 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | — | 12/276 (4.3%) | 227/276 (82.2%) |
| Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | — | 0/78 (0%) | 31/78 (39.7%) |
| Placebo (Randomized Period) | — | 1/79 (1.3%) | 20/79 (25.3%) |
| Event | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|---|
| Attention deficit/hyperactivity disorderPsychiatric disorders | 0/276 | 0/78 | 1/79 |
| SyncopeNervous system disorders | 2/276 | 0/78 | 0/79 |
| AggressionPsychiatric disorders | 2/276 | 0/78 | 0/79 |
| Abdominal painGastrointestinal disorders | 1/276 | 0/78 | 0/79 |
| VomitingGastrointestinal disorders | 1/276 | 0/78 | 0/79 |
| CellulitisInfections and infestations | 1/276 | 0/78 | 0/79 |
| Gastric infectionInfections and infestations | 1/276 | 0/78 | 0/79 |
| WoundInjury, poisoning and procedural complications | 1/276 | 0/78 | 0/79 |
| DehydrationMetabolism and nutrition disorders | 1/276 | 0/78 | 0/79 |
| Abnormal behaviorPsychiatric disorders | 1/276 | 0/78 | 0/79 |
| Event | Lisdexamfetamine Dimesylate (LDX)(Open-label Period) | Lisdexamfetamine Dimesylate (LDX)(Randomized Period) | Placebo (Randomized Period) |
|---|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 76/276 | 3/78 | 0/79 |
| HeadacheNervous system disorders | 58/276 | 6/78 | 5/79 |
| Weight decreasedInvestigations | 46/276 | 2/78 | 1/79 |
| NasopharyngitisInfections and infestations | 43/276 | 7/78 | 3/79 |
| AnorexiaMetabolism and nutrition disorders | 41/276 | 0/78 | 0/79 |
| InsomniaPsychiatric disorders | 39/276 | 1/78 | 1/79 |
| VomitingGastrointestinal disorders | 32/276 | 2/78 | 1/79 |
| NauseaGastrointestinal disorders | 27/276 | 2/78 | 0/79 |
| Abdominal pain upperGastrointestinal disorders | 23/276 | 4/78 | 2/79 |
| Abdominal painGastrointestinal disorders | 20/276 | 2/78 | 0/79 |
| Age, Continuous(years) | All Enrolled Subjects |
|---|---|
| Mean | 10.9 ± 2.82 |
| Age, Customized(Participants) | All Enrolled Subjects |
|---|---|
| 6-12 years | 191 |
| 13-17 years | 85 |
| Sex: Female, Male(Participants) | All Enrolled Subjects |
|---|---|
| Female | 64 |
| Male | 212 |
| Region of Enrollment(Participants) | All Enrolled Subjects |
|---|---|
| United States | 40 |
| Italy | 20 |
| United Kingdom | 16 |
| France | 11 |
| Hungary | 28 |
| Belgium | 9 |
| Poland | 8 |
| Germany | 95 |
| Sweden | 49 |
Ran from Jan 2009 to primary completion in Oct 2011, 32 months.
Results were first posted in Oct 2012, 11 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 32 months is above that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →